MorphoSys (ETR:MOR) received a €114.00 ($132.56) price objective from Goldman Sachs Group in a research report issued on Thursday, September 26th, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 16.74% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. Berenberg Bank set a €150.00 ($174.42) target price on shares of MorphoSys and gave the company a “buy” rating in a report on Monday, September 9th. HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the company a “sell” rating in a report on Friday, August 16th. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research note on Friday, August 9th. Deutsche Bank set a €133.00 ($154.65) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of €119.78 ($139.28).
MorphoSys stock traded up €0.45 ($0.52) during midday trading on Thursday, hitting €97.65 ($113.55). 148,770 shares of the company’s stock were exchanged, compared to its average volume of 153,687. MorphoSys has a 12-month low of €76.45 ($88.90) and a 12-month high of €114.70 ($133.37). The firm’s 50 day simple moving average is €104.39 and its 200 day simple moving average is €95.02. The stock has a market cap of $3.08 billion and a price-to-earnings ratio of -73.92. The company has a debt-to-equity ratio of 8.61, a quick ratio of 7.40 and a current ratio of 7.62.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Read More: What is Liquidity?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.